ADAR1 Capital Management LLC Reduces Position in Context Therapeutics Inc. (NASDAQ:CNTX)

ADAR1 Capital Management LLC reduced its position in shares of Context Therapeutics Inc. (NASDAQ:CNTX) by 6.1% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 351,094 shares of the company’s stock after selling 22,741 shares during the quarter. ADAR1 Capital Management LLC’s holdings in Context Therapeutics were worth $369,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of the company. Landscape Capital Management L.L.C. purchased a new stake in shares of Context Therapeutics in the 4th quarter worth about $94,000. Geode Capital Management LLC boosted its position in Context Therapeutics by 9.2% during the 4th quarter. Geode Capital Management LLC now owns 628,729 shares of the company’s stock valued at $661,000 after acquiring an additional 52,830 shares in the last quarter. Franklin Resources Inc. boosted its position in shares of Context Therapeutics by 115.9% during the fourth quarter. Franklin Resources Inc. now owns 4,003,380 shares of the company’s stock valued at $4,204,000 after purchasing an additional 2,149,392 shares in the last quarter. Clear Harbor Asset Management LLC lifted its holdings in shares of Context Therapeutics by 60.6% during the fourth quarter. Clear Harbor Asset Management LLC now owns 57,804 shares of the company’s stock valued at $61,000 after purchasing an additional 21,804 shares during the last quarter. Finally, Y Intercept Hong Kong Ltd purchased a new position in Context Therapeutics in the third quarter worth about $89,000. 14.03% of the stock is currently owned by hedge funds and other institutional investors.

Context Therapeutics Stock Down 16.7 %

CNTX opened at $0.60 on Monday. The business has a fifty day moving average of $0.80 and a 200 day moving average of $1.33. The stock has a market cap of $53.74 million, a P/E ratio of -0.66 and a beta of 2.18. Context Therapeutics Inc. has a 52-week low of $0.55 and a 52-week high of $2.75.

Context Therapeutics (NASDAQ:CNTX) last issued its quarterly earnings data on Thursday, March 20th. The company reported ($0.04) EPS for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.01. Equities analysts anticipate that Context Therapeutics Inc. will post -0.51 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on CNTX. Citizens Jmp raised shares of Context Therapeutics to a “strong-buy” rating in a report on Wednesday, January 8th. D. Boral Capital reaffirmed a “buy” rating and issued a $9.00 price objective on shares of Context Therapeutics in a research note on Friday, March 21st. JMP Securities began coverage on shares of Context Therapeutics in a report on Wednesday, January 8th. They set an “outperform” rating and a $4.00 price target on the stock. Finally, HC Wainwright reissued a “buy” rating and issued a $5.00 price objective on shares of Context Therapeutics in a research note on Friday, March 21st. Six research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Context Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $6.17.

About Context Therapeutics

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.